Program
sivopixant
Also written as “Sivopixant” and “S-600918”.
Its studies are mostly in Sleep Apnea Syndromes · Chronic Cough, led by Shionogi.
Furthest: phase 2, since Sep 26, 20192 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shionogi | 21 open or running | phase 2since Sep 26, 2019 | Sep 26, 2019 | Dec 31, 2026phase 2 · NCT06776432 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 26, 2019First study: phase 2 study in Chronic CoughFirst studyNCT04110054 · 406 enrolled · United States, Czechia, Japan and more
- Jan 3, 2025Phase 2 study in Sleep Apnea SyndromesNCT06776432 · 60 enrolled · United States
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Sleep Apnea SyndromesNCT06776432
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06776432Sleep Apnea Syndromes · United States | 2 | Active, not recruiting | Dec 31, 2026 | 60 |
| NCT04110054Chronic Cough · United States, Czechia, Japan and more | 2 | Completed | Dec 8, 2020 | 406 |
How it is read
Names in the registry
- “Sivopixant”, 1 entry
- “S-600918”, 1 entry
Conditions, from the studies’ own filings
- Sleep Apnea Syndromes, 1 study
- Chronic Cough, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.